Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader | MicrobiomeTrials← Back to trialsNCT05294731
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2022-05-06Est. Completion: 2029-01-31
Enrollment target: 146 participants Locations- The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China
- Anhui Provincial Hospital, Hefei, Anhui, China
- Peking University Third Hospital, Beijing, Beijing Municipality, China
- Beijing Chao Yang Hospital,Capital Medical University, Beijing, Beijing Municipality, China
- Second Affiliated Hospital of Army Medical University (Xinqiao Hospital), Chongqing, Chongqing Municipality, China
- Fujian Medical University Union Hospital, Fuzhou, Fujian, China
- Sun Yat Sen University Cancer Center, Guangzhou, Guangdong, China
- Guangdong Provincial Peoples Hospital Huifu Branch, Guangzhou, Guangdong, China
- The Peoples Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China
- Nanyang Central Hospital, Nanyang, Henan, China
- Henan Cancer Hospital, Zhengzhou, Henan, China
- Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
- Xiangyang Central Hospital, Xiangyang, Hubei, China
- The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
- Jiangsu Province Hospital, Nanjing, Jiangsu, China
Other microbiome trials you might be interested in
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries. The purpose of this study is to ass…
Duarte, United StatesEst. completion Jul 2027
Non-hodgkin Lymphoma
The most common types of mature B-cell lymphomas (MBLs) in children are Burkitt lymphoma (BL) and diffuse large B-cell l…
Palo Alto, United StatesEst. completion Nov 2028
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Nanchang University Branch Donghu, Nanchang, Jiangxi, ChinaJiangxi Province Cancer Hospital, Nanchang, Jiangxi, ChinaThe First Hospital of Jilin University, Changchun, Jilin, ChinaAffiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning, ChinaShandong Cancer Hospital, Jinan, Shandong, ChinaQingdao Central Hospital, Qingdao, Shandong, ChinaRui Jin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai Municipality, ChinaShanxi Provincial Cancer Hospital, Taiyuan, Shanxi, ChinaWest China Hospital, Sichuan University, Chengdu, Sichuan, ChinaInstitute of Hematology and Hospital of Blood Disease, Tianjin, Tianjin Municipality, ChinaFirst Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, ChinaThe First Affiliated Hospital, Zhejiang University School of Medicine Branch Yuhang, Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, ChinaUrothelial CancerUrinary Bladder Neoplasms
This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together as a bladder pre…
Santa Barbara, United StatesEst. completion Mar 31, 2030